Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

No­var­tis records an­oth­er tislelizum­ab win en route to bring­ing BeiGene's PD-1 to FDA's doors

The lat­est crop of da­ta is out for No­var­tis and BeiGene’s tislelizum­ab as the part­ners look to pad their case for the PD-1 in­hibitor’s ex­pan­sion be­yond Chi­na.

When com­bined with chemother­a­py, the drug “sig­nif­i­cant­ly im­proved” the over­all sur­vival of pa­tients with pre­vi­ous­ly un­treat­ed un­re­sectable, lo­cal­ly ad­vanced, re­cur­rent or metasta­t­ic esophageal squa­mous cell car­ci­no­ma (ES­CC) com­pared to chemo alone. That means the drug met its pri­ma­ry goal, ac­cord­ing to the topline re­sults re­port­ed by the Swiss Big Phar­ma Wednes­day, in the Phase III RA­TIO­NALE 306 study, one of the drug’s more than a dozen late-stage tri­als across 35 coun­tries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.